



# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Nemerow

Serial No.:

09/903,327

Filed:

July 10, 2001

For:

**BIFUNCTIONAL MOLECULES AND VECTORS COMPLEXED THEREWITH FOR** 

TARGETED GENE DELIVERY

Art Unit:

1632

Examiner:

Unassigned

I hereby certify that this paper and the attached papers are being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents

Washington, D.C. 20231, on this date.

10/19/01

Date

Robert Wickman

AMENDMENT AND RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID **SEQUENCE DISCLOSURES** 

Commissioner for Patents Washington, D.C. 20231

Dear Sir:

Responsive to the Notice to Comply and the Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, please amend the above-captioned application as follows:


#### IN THE SEQUENCE LISTING:

Please replace the sequence listing in the above-captioned application with the attached substitute SEQUENCE LISTING in the above-captioned application. A disk copy of the SEQUENCE LISTING accompanies this response.

#### **REMARKS**

Any fees that may be due in connection with this paper or with this application during its entire pendency may be charged to Deposit Account No. 50-1213. If a Petition for extension of time is needed, this paper is to be considered such Petition.

Attached herewith is copy of the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, the Substitute Sequence Listing, disk and paper copies, and a Verified Statement that the content of the paper and computer readable copies are the same. It is believed that no fee is due. However, if it is determined that a fee is due, any fees that may be due in connection with this paper or with this application during its entire pendency may be



charged to Deposit Account No. 50-1213. If a Petition for extension of time is needed, this paper is to be considered such Petition.

The Substitute Sequence Listing differs from the Sequence Listing as originally filed in that the Substitute Sequence Listing corrects the errors noted in the Raw Sequence Listing and Sequence Verification Summary accompanying the Notice to Comply, mailed on August 30, 2001 as follows:

### On Page 1 of the Raw Sequence Listing:

Line 150 has been rectified to identify the priority application by its serial number alone.

#### On Page 2 of the Raw Sequence Listing:

Line 93 has been rectified to reflect the correct nucleotide number.

## On Page 14 of the Raw Sequence Listing:

Line 808 has been rectified by the insertion of the omitted amino acid residue number.

### On Page 19 of the Raw Sequence Listing:

The Sequence Listing was reformatted so as to avoid the wrapping of the nucleics onto the next linhe.

The Substitute Sequence Listing contains no new matter. Accordingly, entry of the Substitute Sequence Listing into the file history of the above-captioned application is respectfully requested.

Respectfully submitted,

HELLER, EHRMAN, WHITE & McAULIFFE LLP

By:

Stephenie L. Seidman Registration No. 33,779

Attorney Docket No. 22908-1228B Address all correspondence to:

HELLER EHRMAN WHITE & McAULIFFE LLP

4350 La Jolla Village Drive, 6th Floor

San Diego, California 92122-1246

Telephone: (858) 450-8400 Facsimile: (858) 587-5360 E-mail: sseidman@HEWM.com